ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 26.6 | 42.2 | 34.6 |
| Other income | 1.9 | 1.8 | 0.6 |
| Total income | 28.5 | 44.0 | 35.2 |
| Profit before exceptional items & tax | 0.1 | 2.6 | 3.4 |
| Profit before tax | 0.1 | 2.6 | 3.4 |
| Net profit | 0.1 | 2.7 | 3.4 |
| Operating margin | 0.4% | 5.9% | 9.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -97.10% |
|---|---|
| Net profit, quarter on quarter | -96.30% |
| Revenue, year on year | -23.10% |
| Operating profit, year on year | -164.30% |
| Operating profit, quarter on quarter | -325.00% |
BSE results filing, NSE: BAFNAPH. Figures extracted from the filing.
Bafna Pharmaceuticals Ltd: key numbers
- Share price
- ₹482.25
- Market cap
- ₹1,141 Cr
- Revenue (annual)
- ₹150.6 Cr
- Net profit (annual)
- ₹11.10 Cr
- P/E (TTM)
- 99.1×Sector 43.8×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 9.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bafna Pharmaceuticals Ltd
All →Bafna Pharmaceuticals Q2 FY27 Results: Net Profit ₹6.8 Cr, Up 119.4% YoY
Bafna Pharmaceuticals' board approved unaudited financial results for the quarter and half year ended 30 September 2026, with a limited review report. Quarterly revenue from operations was ₹47.67 Crore, versus ₹35.47 Crore a year earlier.
- Key figure
- Net profit ₹6.8 Cr · +119.4% YoY
Bafna Pharmaceuticals Board Meeting Date
Bafna Pharmaceuticals will consider unaudited standalone quarterly results on 11 November 2026. Trading window stays closed until 13 November 2026.
Bafna Pharmaceuticals Other Announcement
Bafna Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
Bafna Pharmaceuticals Annual General Meeting
Bafna Pharmaceuticals' 31st AGM held on September 11, 2026 approved adoption of audited financials, a director re-appointment, and cost auditor ratification. No specific monetary transaction was transacted.
Bafna Pharmaceuticals Annual Report
Bafna Pharmaceuticals Limited has submitted its Annual Report for the financial year 2025-2026 and announced the date for its 31st Annual General Meeting.
Bafna Pharmaceuticals Annual General Meeting
Bafna Pharmaceuticals Limited will hold its 31st Annual General Meeting on September 11, 2026. The book closure is scheduled from September 05 to September 11, 2026.